What is SMA? A Comprehensive Guide to Spinal Muscular Atrophy

What Is Spinal Muscular Atrophy (SMA)?

Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the motor neurons in the spinal cord. These specialised nerve cells are responsible for sending signals from the brain to the muscles, allowing the body to perform voluntary movements such as walking, sitting, breathing, and swallowing. In individuals with Spinal Muscular Atrophy, these motor neurons gradually degenerate and die, leading to progressive muscle weakness and muscle wasting.

SMA most commonly appears in infancy or early childhood, although some forms can develop later in adolescence or adulthood. The severity of Spinal Muscular Atrophy varies widely depending on the type of the condition and the amount of survival motor neuron (SMN) protein the body is able to produce.

How Spinal Muscular Atrophy Affects the Body

In people with Spinal Muscular Atrophy, the loss of motor neurons disrupts the communication between the nervous system and the muscles. Without proper nerve signals, muscles gradually weaken and shrink due to lack of use. This muscle weakness typically affects muscles closest to the centre of the body first, including those in the shoulders, hips, thighs, and upper back.

As Spinal Muscular Atrophy progresses, individuals may experience difficulties with mobility, posture, swallowing, and breathing. The degree of these difficulties differs depending on the type of SMA and how early the condition begins.

The Genetic Cause of Spinal Muscular Atrophy

Spinal Muscular Atrophy is caused by mutations or deletions in a gene called SMN1 (Survival Motor Neuron 1). This gene is responsible for producing the SMN protein, which is essential for the survival and proper functioning of motor neurons. When the SMN1 gene does not work correctly, the body produces insufficient amounts of this protein, resulting in the gradual degeneration of motor neurons.

The condition follows an autosomal recessive inheritance pattern, meaning that a child must inherit the faulty gene from both parents to develop the disease. In many cases, parents are healthy carriers who do not show symptoms themselves.

To improve early detection and prevention, many countries have introduced Genetic Screening Programmes that help identify carriers and diagnose Spinal Muscular Atrophy in newborns. Early identification through these programmes can significantly improve treatment outcomes, as modern therapies are most effective when started as early as possible.

Common Symptoms and Early Warning Signs

Spinal Muscular Atrophy (SMA) is characterised by progressive muscle weakness caused by the loss of motor neurons in the spinal cord. The symptoms of Spinal Muscular Atrophy can vary depending on the type of SMA and the age at which the condition begins. However, many individuals share a number of common signs related to muscle weakness and reduced motor control. Recognising these early warning signs is important because early diagnosis can lead to faster access to treatment and supportive care.

Early Signs in Infants and Young Children

In infants and very young children, the first symptoms of Spinal Muscular Atrophy often involve delays in physical development and difficulties with basic motor skills. Parents or healthcare providers may notice that a baby appears unusually “floppy” due to low muscle tone, a condition known as hypotonia.

Common early signs include:

• Difficulty lifting or controlling the head
• Limited movement of the arms and legs
• Weak crying or difficulty swallowing
• Trouble sitting without support
• Delayed motor milestones such as rolling over or crawling

In more severe forms of Spinal Muscular Atrophy, breathing muscles may also be affected, which can lead to rapid or shallow breathing and increased vulnerability to respiratory infections.

Symptoms in Older Children and Adults

When Spinal Muscular Atrophy develops later in childhood or adulthood, the symptoms may appear more gradually. Individuals may initially notice muscle weakness in the legs, making activities such as running, climbing stairs, or standing from a seated position more difficult.

Typical symptoms in later-onset Spinal Muscular Atrophy include:

• Progressive weakness in the hips, thighs, and shoulders
• Frequent falls or difficulty maintaining balance
• Muscle fatigue after mild physical activity
• Trembling or fine shaking of the fingers (tremor)
• Difficulty rising from the floor or low chairs

Although Spinal Muscular Atrophy mainly affects voluntary muscles, cognitive abilities and intellectual development remain normal.

Why Early Detection Matters

Identifying the early warning signs of Spinal Muscular Atrophy is essential because modern treatments can significantly slow disease progression when started early. Early diagnosis allows patients to access medical care, physiotherapy, respiratory support, and new gene-based therapies that can improve long‑term outcomes and quality of life.

 

Causes of SMA and How It Is Inherited

Spinal Muscular Atrophy (SMA) results from a genetic defect that prevents the body from producing enough SMN protein, essential for motor‑neuron survival. Understanding the SMN1 and SMN2 genes, along with the inheritance pattern, helps families assess risk and benefit from early testing.

Core genetic factors that influence the development and severity of SMA.

SMN1 Gene Defect

The primary cause of SMA.

Mutations or deletions in the SMN1 gene prevent the body from producing enough SMN protein. As motor neurons deteriorate, muscles weaken due to lack of nerve stimulation.

The SMN2 Backup Gene

Influences severity of symptoms.

SMN2 produces small amounts of SMN protein. Fewer copies usually mean more severe SMA, while more copies often result in milder forms, creating variation even among individuals with the same SMN1 mutation.

Autosomal Recessive Inheritance

How SMA is passed on.

A child must inherit two faulty SMN1 copies—one from each parent—to develop SMA. Carrier parents are symptom‑free but have a 25% chance of having an affected child in each pregnancy.

Importance of Carrier Testing

Identifying risk early.

Because carriers have no symptoms, testing is key for families planning a pregnancy. Modern screening— including newborn testing in some regions—supports early diagnosis and timely treatment.

Key Takeaway:

SMA is caused by defects in the SMN1 gene, shaped by SMN2 copy number, and inherited in an autosomal recessive pattern—making early carrier screening and genetic counselling essential for informed family planning.

How Spinal Muscular Atrophy Is Diagnosed

Diagnosing Spinal Muscular Atrophy (SMA) involves a combination of clinical evaluation, genetic testing, and supportive diagnostic tools that help assess muscle strength and nerve function. Early and accurate diagnosis is crucial, as modern treatments for Spinal Muscular Atrophy are most effective when started as soon as possible.

Clinical Examination and Medical History

The diagnostic process often begins with a thorough clinical assessment. A healthcare professional will:

• Evaluate muscle tone and strength
• Observe motor development milestones
• Check for signs such as hypotonia, delayed movement, or decreased reflexes
• Review family history for any genetic conditions

Although these signs may raise suspicion of Spinal Muscular Atrophy, clinical observation alone cannot confirm a diagnosis.

Genetic Testing (The Primary Diagnostic Method)

A definitive diagnosis of Spinal Muscular Atrophy is made through a genetic blood test that checks for deletions or mutations in the SMN1 gene. This test is highly accurate and can confirm nearly all cases of SMA.

Key points:

• Most individuals with Spinal Muscular Atrophy have a complete SMN1 deletion
• The test may also determine the number of SMN2 gene copies
• SMN2 copy count helps predict the severity of the condition

Because genetic testing is reliable and minimally invasive, it is considered the gold standard for diagnosing SMA.

Newborn Screening

In many countries, Spinal Muscular Atrophy is included in routine newborn screening. A small blood sample is taken shortly after birth to detect SMN1 gene deletions.

Benefits of newborn screening:

• Allows diagnosis before symptoms appear
• Enables early treatment, which can significantly improve outcomes
• Reduces diagnostic delays that were common in the past

Early detection through newborn screening is now considered best practice, particularly as effective therapies become more widely available.

Electromyography (EMG) and Nerve Conduction Studies (NCS)

Although genetic testing is usually sufficient, additional tests may be used to assess muscle and nerve function—especially if symptoms are unclear or if another neuromuscular condition is suspected.

These tests can include:

• EMG to measure electrical activity in muscles
• NCS to evaluate nerve signal speed and strength

Findings typically show reduced nerve stimulation of muscles, consistent with Spinal Muscular Atrophy.

Muscle Biopsy (Rarely Used Today)

Before genetic testing became widely accessible, muscle biopsy was more common. Today, it is rarely required. A biopsy might be considered only in unusual or uncertain cases where genetic results are inconclusive.

Why an Early Diagnosis Matters

Diagnosing Spinal Muscular Atrophy early enables individuals to access:

• Disease-modifying treatments
• Respiratory and nutritional support
• Physiotherapy and mobility assistance
• Family genetic counselling

Early intervention can dramatically improve long-term prognosis and quality of life for people with Spinal Muscular Atrophy.

Current Treatment Options and Emerging Therapies

In recent years, the landscape for treating Spinal Muscular Atrophy (SMA) has undergone a dramatic transformation. Historically, medical care was primarily supportive, focusing on managing symptoms rather than addressing the underlying genetic cause. Today, several disease-modifying therapies (DMTs) are available that have significantly improved survival rates and motor function for individuals with Spinal Muscular Atrophy.

Disease-Modifying Therapies (DMTs)

Modern treatments for Spinal Muscular Atrophy work by either increasing the production of the SMN protein from the SMN2 “back-up” gene or by replacing the function of the missing SMN1 gene.

1. Nusinersen (Spinraza)

Nusinersen was the first approved treatment for Spinal Muscular Atrophy. It is an antisense oligonucleotide (ASO) designed to target the SMN2 gene, encouraging it to produce a more functional version of the SMN protein.

• Administration: It is delivered via an intrathecal injection (into the fluid surrounding the spinal cord).
• Effectiveness: It has been shown to improve motor function and slow disease progression across various types of SMA.

2. Onasemnogene Abeparvovec (Zolgensma)

This is a revolutionary form of gene therapy. It works by delivering a fully functional copy of the SMN1 gene directly into the patient’s cells using a specialised viral vector.

• Administration: It is a one-time intravenous infusion.
• Effectiveness: By providing the body with the instructions to make the SMN protein itself, it can stop the progression of Spinal Muscular Atrophy, especially when administered to infants before significant motor neuron loss has occurred.

3. Risdiplam (Evrysdi)

Risdiplam is the first oral medication approved for Spinal Muscular Atrophy. Like Nusinersen, it targets the SMN2 gene to boost protein production, but it is distributed throughout the entire body.

• Administration: A daily liquid dose taken at home.
• Effectiveness: It provides a non-invasive option for patients of all ages and has shown significant benefits in improving muscle control and respiratory health.

Supportive and Multidisciplinary Care

While genetic therapies target the root cause, comprehensive care remains essential for managing the daily challenges of Spinal Muscular Atrophy. A multidisciplinary team of specialists usually includes:

• Physiotherapists: To maintain joint flexibility and optimise muscle strength.
• Respiratory Therapists: To provide breathing support and help clear secretions from the lungs.
• Nutritional Specialists: To ensure adequate calorie intake and manage swallowing difficulties (dysphagia).
• Orthopaedic Surgeons: To monitor and treat complications such as scoliosis (curvature of the spine).

Emerging Therapies and Research

Research into Spinal Muscular Atrophy is ongoing, with scientists exploring new ways to enhance treatment outcomes. Some of the most promising emerging areas include:

• Muscle-Directed Therapies: Unlike current treatments that focus on nerves, these “myostatin inhibitors” aim to act directly on the muscles to increase their mass and strength.
• Combination Therapies: Researchers are investigating whether using two different types of treatment (e.g., gene therapy followed by an oral drug) can provide even better results than a single therapy alone.
• Improved Delivery Systems: New methods are being developed to ensure that treatments reach the central nervous system more effectively and with fewer side effects.

The rapid development of these therapies has changed Spinal Muscular Atrophy from a life-limiting condition into a manageable one for many, offering hope to families worldwide.